Related Experiment Video

Updated: Jul 4, 2026

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

Abciximab: a review and update for clinicians

Ernest L Mazzaferri1, John J Young

  • 1200 Davis Heart & Lung Research Institute, 473 W 12th Avenue, Columbus, OH 43210-1252, USA. ernest.mazzaferri@osumc.edu

Expert Review of Cardiovascular Therapy
|May 31, 2008
PubMed

Insights

Abciximab is a recommended glycoprotein (GP) IIb/IIIa inhibitor for ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. It offers unique benefits like no renal dosing and reversible effects with platelet transfusions.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • The glycoprotein (GP) IIb/IIIa receptor is crucial in platelet aggregation and thrombus formation.
  • GP IIb/IIIa inhibitors are vital for managing acute coronary syndromes and percutaneous coronary interventions.
  • Abciximab is an established intravenous GP IIb/IIIa inhibitor with distinct characteristics.

Purpose of the Study:

  • To highlight the role of GP IIb/IIIa receptors in thrombosis.
  • To compare abciximab with other intravenous GP IIb/IIIa inhibitors.
  • To emphasize abciximab's unique properties and guideline recommendations.

Main Methods:

  • Review of current guidelines and clinical evidence.
  • Comparative analysis of intravenous GP IIb/IIIa inhibitors.
  • Focus on abciximab's pharmacological profile and clinical utility.

Main Results:

  • Abciximab is highly recommended by major cardiology guidelines for ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention.
  • Abciximab demonstrates unique advantages, including the absence of a requirement for renal dose adjustment.
  • The inhibitory effects of abciximab on platelet function are largely reversible through platelet transfusions.

Conclusions:

  • Abciximab is a preferred GP IIb/IIIa inhibitor for specific high-risk cardiovascular interventions.
  • Its favorable dosing profile and reversibility enhance its clinical applicability.
  • Abciximab represents a dependable therapeutic option in interventional cardiology.

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...